drugset / Trial / NCT04254549

Rifaximin in Patients With Diabetic Gastroparesis

NCT04254549

Phase 2 Terminated 5 enrolled Mayo Clinic
RandomizedParallel-groupDouble-blindTreatment

Summary

Researchers are trying to determine if subjects with diabetic gastroparesis and symptoms of bloating will have a greater improvement in bloating symptoms when treated with rifaximin.

Timeline

Start
2019-06-14
Primary completion
2025-04-08
Completion
2025-04-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Rifaximin Other / unclassified 550 mg Oral